Metagenomi Inc (MGX)
Metagenomi Inc. is a biotechnology company focused on in vivo genome editing and the development of potentially curative genetic medicines in the United States. Its lead development program, MGX-001, is designed for adults and children with hemophilia and is intended to provide long-term protection against bleeding events and joint damage. The company also has a collaboration agreement with Ionis Pharmaceuticals covering several programs, including apolipoprotein C-III for hypertriglyceridemia, transthyretin (TTR) for transthyretin amyloidosis, and angiotensinogen (AGT) for refractory hypertension. Founded in 2016 and based in Emeryville, California, the company was previously known as Metagenomi, Inc. and adopted the name Metagenomi Therapeutics, Inc. in January 2026. Its common stock is listed on NASDAQ under the symbol MGX.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-MGX
|
$1.36
|
23.3% Upside
|
Undervalued
|
$7
|
536.4% Upside
|
Bargain
|
Weak
|
0.0%
|
November 18, 2026
|
0.4x
|
3.1x
|
41.555 M
|
-41.389 M
|
46.9%
|
67.5%
|
-1.8
|
91.8%
|
